Trial intelligence / Profile preview

JCOG1805 PanDRa-BD adjuvant chemotherapy for high-risk stage II colorectal cancer

jRCTs031190186Recruiting

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Start
Jan 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Randomised trial of capecitabine and oxaliplatin in colorectal cancer (CRC) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Relapse-free survival. Started Jan 2020; status: recruiting.

02

Drugs

capecitabineoxaliplatin
03

Conditions

colorectal cancer (CRC)

Beyond the preview

Go deeper on jRCTs031190186.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCTs031190186.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call